AbbVie Inc. is a global research-based biopharmaceutical company headquartered in North Chicago, Illinois, operating across more than 175 countries and treating patients across immunology, oncology, neuroscience, eye care, and aesthetics. Its ESG program is anchored in three pillars: Patient-First Innovation, Maintaining a Resilient Business, and Human-Focused Progress, with Environmental Sustainability identified as a standalone priority. The most current primary disclosures are the 2024 ESG Action Report and the 2024 ESG Disclosure Supplement, with select KPIs subject to limited third-party assurance from Ernst & Young LLP.

AbbVie holds SBTi-validated near-term climate targets, validated by the Science Based Targets initiative in March 2023, aligning its decarbonization path with a 1.5°C trajectory. The company has been included in the Dow Jones Sustainability World and North America Indices, earned a Top 1% S&P Global ESG Score, and was named to the FORTUNE 100 Best Companies to Work For for the sixth consecutive year as of 2023.

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf
https://www.abbvie.com/sustainability/environmental-social-and-governance.html

Sustainability Strategy and Goals

AbbVie’s ESG framework is governed through a formal ESG Council chaired by the Senior Vice President for Corporate Affairs, with cross-functional senior leaders as members. Named Executive Officers carry a formal ESG goal weighted at 10% in their short-term incentive compensation structure, embedding accountability directly into annual pay. The company aligns its strategy with the UN SDGs and reports under SASB, TCFD, and the GHG Protocol, with EY providing third-party limited assurance on select KPIs.

Net Zero and Carbon Emissions

AbbVie’s SBTi-validated target calls for a 42% absolute reduction in Scope 1 and 2 GHG emissions by 2030 against a 2021 base year. The 2021 baseline totals 624,662 metric tons CO2e (Scope 1: 367,954 MT, Scope 2 market-based: 256,708 MT), and the 2030 reduction target is 362,304 metric tons CO2e.​

• Scope 1 GHG: 367,954 MT CO2e (2021 baseline) → 342,607 MT CO2e (2022) → 328,259 MT CO2e (2023) → 300,072 MT CO2e (2024), a 18.5% reduction from baseline
• Scope 2 market-based GHG: 256,708 MT CO2e (2021 baseline) → 184,549 MT CO2e (2022) → 131,232 MT CO2e (2023) → 122,287 MT CO2e (2024), a 52.4% reduction from baseline
• Total Scope 1+2 (market-based): 624,662 MT CO2e (2021 baseline) → 527,156 MT CO2e (2022) → 459,491 MT CO2e (2023) → 422,359 MT CO2e (2024), a 32.4% reduction from baseline
• GHG intensity per USD million revenue: 9.08 MT CO2e (2022) → 8.46 MT CO2e (2023) → 7.50 MT CO2e (2024), an 11.4% year-over-year decrease from 2023 to 2024​

Water Stewardship

AbbVie targets a 20% absolute reduction in water withdrawal versus a 2015 baseline by 2025. The company had achieved a 17% reduction as of 2023 reporting, leaving a 3-percentage-point shortfall as the target year closed.​

• Absolute water withdrawal: 28.94 million m³ (2022) → 28.98 million m³ (2023) → 28.85 million m³ (2024)​
• Net water intake: 5.04 million m³ (2022) → 4.80 million m³ (2023) → 4.80 million m³ (2024), a 4.8% reduction over two years​
• Progress against 2025 water target: 17% reduction achieved as of 2023, against a required 20%​

Regenerative Agriculture

AbbVie does not operate in agriculture directly. Its supply chain sustainability focus targets upstream Scope 3 categories including purchased goods, capital goods, and upstream transportation. The company’s SBTi supplier engagement target requires 79.1% of suppliers by emissions to set science-based targets by 2027, covering these three Scope 3 categories. No direct regenerative agriculture programs appear in AbbVie’s 2023 or 2024 ESG disclosures.

Deforestation and Biodiversity

AbbVie’s 2023 EcoChallenge initiative, joined by approximately 3,250 employees from 51 countries, resulted in the planting of more than 700 trees and kept 21,000 plastic bottles out of landfill. The company’s Environmental Management System is certified to ISO 14001 at 50% of its global manufacturing and R&D sites. Formal, quantified deforestation and biodiversity targets with measurable baselines are not yet publicly disclosed in AbbVie’s ESG reports.​

Packaging and Circular Economy

AbbVie targets zero waste to landfill (excluding leased commercial offices) by 2035 and a 50% combined recycling rate for hazardous and non-hazardous waste by 2025. The 50% recycling target has not been met, with 2024 performance at 36.8%, below even the 2023 level of 40%.

• Combined hazardous and non-hazardous recycling rate: 39% (2022) → 40% (2023) → 36.8% (2024), against a 50% target for 2025​
• Total waste (hazardous and non-hazardous): 33,900 MT (2022) → 30,200 MT (2023) → 33,200 MT (2024)​
• Absolute waste reduction vs. 2015 baseline: 21.7% by 2024, surpassing the 20% target set for 2025​
• Landfilled hazardous waste: 0.005 thousand MT (2023) → 0.003 thousand MT (2024)​
• Landfilled non-hazardous waste: 3.34 thousand MT (2023) → 2.83 thousand MT (2024)​
• Spark Innovation Accelerator (since 2019): 51 winning initiatives, collectively diverting 600 MT of waste from landfill​

Human Rights and Responsible Sourcing

AbbVie requires all clinical studies to comply with the World Medical Association’s Declaration of Helsinki, International Council for Harmonization (ICH) standards, and Good Clinical Practice principles. Its Supplier Code of Conduct governs expectations around ethics, labor, human rights, and environmental management, with critical suppliers audited at minimum every three years.​

• Total supplier spend: $15.038B (2022) → $15.188B (2023) → $15.725B (2024)​
• Anti-bribery and anti-corruption training completion: 99% in 2022, 2023, and 2024​
• Code of Business Conduct certification rate: 99% in all three reporting years​
• Supplier SBTi coverage: 13.4% (2021) → 23% (2022) → 41.6% (2023), against a 79.1% target by 2027

Nutrition and Health

AbbVie’s myAbbVie Assist program provides free medicine to U.S. patients who cannot afford it, reaching 238,749 patients in 2024, up from 198,196 in 2022. AbbVie products and devices treat more than 75 conditions globally and reach over 60 million patients annually across 175 countries.​

• U.S. patients receiving medicine at no cost: 198,196 (2022) → 218,407 (2023) → 238,749 (2024)​
• Low- to middle-income countries receiving product donations: 63 (2022) → 76 (2023) → 63 (2024)​
• Adjusted R&D investment: $7.1B (2022) → $7.8B (2023) → $10.8B (2024)​

Community and Social Impact

AbbVie’s philanthropic donations reached $54.1 million in 2024, growing from $38.7 million in 2022. Employee volunteer participation reached 20,230 in 2024, up from 15,879 in 2022, and the Employee Giving Campaign raised $25.0 million for nonprofits in 2024.​

• Philanthropic donations: $38.7M (2022) → $37.8M (2023) → $54.1M (2024)​
• Employee community volunteers: 15,879 (2022) → 17,197 (2023) → 20,230 (2024)​
• Disaster relief donations: $1.5M (2022) → $4.7M (2023) → $2.6M (2024)​
• Employee Giving Campaign: $25.0M raised for nonprofits in 2024​

Governance and Transparency

AbbVie’s board committees covering ESG oversight include the Public Policy and Sustainability Committee, the Nominations and Governance Committee, the Audit Committee, and the Compensation Committee. Select ESG KPIs receive limited assurance from EY LLP annually. The company is evaluating voluntary disclosure under IFRS S2 following the absorption of TCFD recommendations into International Sustainability Standards Board standards.

Technology and Innovation

AbbVie’s decarbonization plan rests on five pillars: energy efficiency (projected 5–7% Scope 1+2 reduction by 2030), renewable energy sourcing (25–30% reduction), fleet electrification (7–10% reduction), physical footprint reduction (10–15% reduction), and supplier engagement. The Spark Innovation Accelerator has driven bottom-up sustainability ideation, and 51 winning solutions since 2019 have delivered reductions of 7,000 MT CO2e, saved 1.6 million kWh, cut water use by 46,000 m³, and diverted 600 MT of waste.

• Total energy consumption: 2,449,768 MWh (2022) → 2,317,472 MWh (2023) → 2,213,805 MWh (2024), a 9.6% reduction over two years​
• Renewable energy consumed: 245,433 MWh (2022) → 298,765 MWh (2023) → 326,424 MWh (2024), a 33% increase over two years​
• Active sourcing of renewable electricity: 29.5% (2021 baseline) → 55.5% (2023), advancing toward 100% by 2030
• HFC emissions (Scope 1 non-carbon): 5,182 MT (2022) → 4,648 MT (2023) → 2,305 MT (2024), a 55% reduction in two years​

Global Partnerships and Advocacy

AbbVie is a member of the UN Global Compact and participates in the Pharmaceutical Product Stewardship Work Group through MED-Project for medicine take-back programs. The company’s SBTi-validated supplier engagement target requires 79.1% of Scope 3 supplier emissions to be covered by science-based targets by 2027. AbbVie reports under SASB, TCFD, the GHG Protocol, and the UN SDGs, with external validation supporting credibility across these frameworks.

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/decarbonization-plan.pdf

Progress vs. Target Tracker

Commitment	Target	Current Status	Assessment
Reduce absolute Scope 1+2 GHG by 42% vs. 2021	2030	32.4% reduction achieved by 2024	On Track
Increase active sourcing of renewable electricity to 100%	2030	55.5% active sourcing achieved as of 2023 ​	On Track
79.1% of suppliers by emissions to set SBTi targets	2027	41.6% coverage as of end of 2023 ​	On Track (needs acceleration)
Reduce absolute water withdrawal by 20% vs. 2015	2025	17% reduction achieved as of 2023 ​	Missed (3pp shortfall at deadline)
Reduce total waste by 20% vs. 2015	2025	21.7% reduction achieved by 2024 ​	Achieved
50% combined recycling rate for hazardous and non-hazardous waste	2025	36.8% in 2024, down from 40% in 2023 ​	Missed
Zero waste to landfill (excl. leased commercial offices)	2035	Landfill volumes declining; 0.003 thousand MT hazardous to landfill in 2024 ​	On Track
Net zero GHG emissions across all scopes	2050	Near-term SBTi targets validated; long-term pathway in development ​	On Track

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf
https://www.abbviecontractmfg.com/news-and-insights/2024-esg-action-report-review.html

Key Sustainability Innovations and Technologies

AbbVie’s decarbonization portfolio combines capital investment in energy efficiency with renewable procurement and operational redesign across its global manufacturing and R&D footprint. A co-generation power system was installed at its Barceloneta, Puerto Rico, site to ensure resilience against grid disruption, and electrical generators were installed at Branchburg, New Jersey, and Waco, Texas. The La Madeleine-de-Nonancourt logistics site in France was modernized with high-efficiency heating systems, replacing aging gas and oil boilers and a fibro-cement roof, reducing site carbon emissions by more than 200 MT CO2e per year.​

The EcoSolvent project at South San Francisco replaced glass bottle solvent delivery with reusable metal tanks hooked directly into the laboratory system, reducing packaging waste and eliminating vapor exposure risk. AbbVie’s All Hands On Deck team at Lake County, Illinois, piloted biodegradable nitrile gloves across labs and began scaling the program to other sites.​

• Spark Innovation Accelerator (active since 2019): 51 winning solutions reducing 7,000 MT CO2e, saving 1.6 million kWh of energy, cutting water use by 46,000 m³, and diverting 600 MT of waste from landfill​
• Fleet electrification: AbbVie projects a 7–10% reduction in Scope 1 fleet emissions by 2030 through EV and hybrid replacement of internal combustion engine vehicles; fleet growth since 2021 has produced a net 1% increase in fleet Scope 1 emissions, offsetting early gains​
• Physical footprint reduction: consolidation of post-Allergan commercial affiliate offices and manufacturing redundancies is projected to cut Scope 1+2 emissions by 10–15% by 2030; footprint rationalization had already contributed approximately 17% of achieved reductions by 2023​
• Reusable packaging: a pilot to replace single-use shipping containers between Ludwigshafen, Germany, and Sligo, Ireland, with reusable plastic Eco-Box containers is underway​
• Renewable energy sourcing: active renewable electricity sourcing advanced from 29.5% in 2021 to 55.5% in 2023, contributing the largest share of Scope 2 reduction, with renewable energy consumed rising from 245,433 MWh (2022) to 326,424 MWh (2024)

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/decarbonization-plan.pdf

Measurable Impacts

AbbVie’s environmental performance shows consistent downward trends in GHG emissions and energy consumption over the 2022 to 2024 period, with EY providing third-party limited assurance on key metrics. Scope 2 market-based emissions fell from 184,549 MT CO2e in 2022 to 122,287 MT CO2e in 2024, a 33.7% reduction in two years, driven by renewable electricity procurement. Scope 1 emissions dropped from 342,607 MT CO2e to 300,072 MT CO2e over the same period, a 12.4% reduction reflecting energy efficiency and footprint rationalization.​

• Total Scope 1+2 (market-based): 527,156 MT CO2e (2022) → 459,491 MT CO2e (2023) → 422,359 MT CO2e (2024), a 19.9% reduction in two years​
• Total energy consumption: 2,449,768 MWh (2022) → 2,317,472 MWh (2023) → 2,213,805 MWh (2024), a 9.6% reduction​
• Total renewable energy consumed: 245,433 MWh (2022) → 298,765 MWh (2023) → 326,424 MWh (2024), a 33% increase​
• Net water intake: 5.04 million m³ (2022) → 4.80 million m³ (2023) → 4.80 million m³ (2024), flat year-over-year 2023 to 2024​
• Absolute waste (hazardous and non-hazardous): 33,900 MT (2022) → 30,200 MT (2023) → 33,200 MT (2024)​
• Recordable incident rate (per 200,000 hours): 0.18 (2022) → 0.181 (2023) → 0.13 (2024), the lowest in the three-year window​
• Work-related employee fatalities: 0 in 2022, 2023, and 2024​
• HFC non-carbon Scope 1 emissions: 5,182 MT (2022) → 4,648 MT (2023) → 2,305 MT (2024), a 55% reduction in two years​
• GHG intensity (MT CO2e per USD million revenue): 9.08 (2022) → 8.46 (2023) → 7.50 (2024)​

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf

Challenges and Areas for Improvement

AbbVie’s most significant unresolved gap is its 50% recycling rate target for 2025. The actual rate was 36.8% in 2024, down from 40% in 2023 and 39% in 2022, a trend moving in the wrong direction as the deadline year closed. The water withdrawal target of 20% reduction by 2025 ended at 17% as of 2023 reporting, a shortfall of 3 percentage points that was not publicly closed in the 2024 disclosures.

Scope 3 supplier engagement remains a structural challenge. Only 41.6% of suppliers by emissions had set SBTi-aligned targets by end of 2023, against a 2027 requirement of 79.1%. Reaching that threshold requires adding roughly 37 percentage points of coverage in fewer than four years, with no published 2024 mid-point progress update.

• Recycling rate shortfall: 36.8% actual vs. 50% target by 2025; declining from 40% in 2023​
• Water target: 17% reduction achieved vs. 20% target by 2025, with 2024 data showing withdrawal at 28.85 million m³, still above the required level
• Scope 3 supplier SBTi gap: 41.6% coverage (end of 2023) vs. 79.1% required by 2027; no 2024 update published​
• Waste uptick: After reaching a low of 30,200 MT in 2023, total waste rose to 33,200 MT in 2024, a 9.9% year-over-year increase​
• Fleet emissions: Fleet growth since 2021 produced a net 1% increase in fleet Scope 1 emissions, working against the 7–10% projected reduction from electrification​
• Renewable electricity: Active sourcing stands at 55.5% (2023), but the raw 2024 data shows non-renewable purchased electricity at 430,504 MWh vs. 324,649 MWh of renewable purchased electricity, indicating a continuing dependence on unbundled RECs to reach stated percentages​
• No time-bound deforestation, biodiversity, or nature-based targets published as of the 2024 ESG Action Report​

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/decarbonization-plan.pdf

Future Plans and Long-Term Goals

AbbVie’s 2030 roadmap is structured around five decarbonization levers, each carrying a projected emissions reduction range. Beyond 2030, AbbVie states it continues to evaluate frameworks, additional targets, and technologies to support long-term decarbonization, with an ultimate net zero goal for 2050. The company has not yet published a post-2030 interim milestone or a formal 1.5°C-aligned long-term SBTi target covering Scope 3.​

• Energy efficiency projects: projected Scope 1+2 reduction of 5–7% by 2030, funded through a centralized CapEx fund​
• Renewable electricity: commitment to 100% active sourcing by 2030, from a 29.5% baseline in 2021 and 55.5% achieved in 2023, accounting for a projected 25–30% Scope 2 reduction​
• Fleet electrification: transition from internal combustion engine vehicles to hybrid and EV, projected to yield a 7–10% Scope 1 fleet reduction by 2030​
• Physical footprint reduction: consolidation of post-Allergan commercial affiliate real estate and manufacturing capacity, projected to yield a 10–15% Scope 1+2 reduction by 2030​
• Supplier SBTi engagement: 79.1% of suppliers by emissions to hold science-based targets by 2027, covering Scope 3 categories 1, 2, and 4​
• Zero waste to landfill (excluding leased commercial offices): target year 2035, with landfilled hazardous waste already at 0.003 thousand MT in 2024​

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/decarbonization-plan.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf

Comparisons to Industry Competitors

AbbVie’s nearest peers by revenue, therapeutic focus, and ESG reporting maturity are Pfizer and Johnson & Johnson. Both have published verifiable ESG performance data covering the same KPI categories, enabling a structured comparison.

Metric	AbbVie	Pfizer	Johnson & Johnson
Scope 1+2 reduction (vs. baseline)	32.4% vs. 2021, by 2024	15% vs. 2019, by 2024 ​	Carbon neutral in operations by 2030 target; Scope 1+2 reductions tracked but specific % not verified in this report ​
Scope 3 supplier coverage	41.6% of suppliers with SBTi targets (2023) ​	51% of suppliers by spend (2023); ~65% (2024) ​	Supplier engagement program active; specific SBTi % not publicly confirmed in this analysis ​
Renewable energy coverage	55.5% active sourcing (2023); 14.7% of total consumed (2024)	14% of electricity demand from renewables (2024) ​	100% renewable electricity target by 2025; progress data not confirmed in this analysis ​
Recycled or sustainable packaging	36.8% waste recycling rate; reusable Eco-Box pilot active (2024)	55% of manufacturing sites at zero-landfill; Pfizer Clear packaging tool deployed ​	Recyclable packaging commitments in place; specific diversion rates not verified in this analysis
Net zero target year	2050 (long-term; SBTi near-term to 2030) ​	2040 (95% Scope 1+2, 90% Scope 3 vs. 2019) ​	2045 (net zero across value chain) ​
Waste diversion / landfill rate	Landfilled non-hazardous waste: 2.83 thousand MT (2024); 21.7% absolute waste reduction vs. 2015 ​	6% of total waste to landfill (2024); 55% of manufacturing sites at zero-landfill ​	Zero waste to landfill target across manufacturing sites; specific diversion rates not verified in this analysis

AbbVie’s absolute Scope 1+2 reduction of 32.4% from a 2021 baseline by 2024 outpaces Pfizer’s 15% reduction from a 2019 baseline over a comparable period, though different baseline years limit direct comparability. Pfizer’s net zero target year of 2040 is a decade ahead of AbbVie’s 2050 goal, and Pfizer’s 65% supplier SBTi coverage in 2024 significantly surpasses AbbVie’s 41.6% as of 2023. On waste performance, Pfizer’s 6% landfill rate across a broader and larger manufacturing base represents a more advanced circular position than AbbVie’s current recycling rate of 36.8%.

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf
https://thesustainableinnovation.com/pfizer-sustainability/
https://ditchcarbon.com/organizations/abbvie
https://tracenable.com/company/johnson-and-johnson/ghg-emissions

What to Watch: 12 to 18 Month Indicators

Three specific signals will define whether AbbVie’s sustainability trajectory holds or weakens over the next 12 to 18 months.

Supplier SBTi coverage update for 2024. AbbVie published no 2024 update on the percentage of suppliers by emissions holding SBTi targets. The 2023 figure of 41.6% against a 2027 requirement of 79.1% already shows a significant gap. A published 2024 figure will reveal whether the company is on pace to close the 37-percentage-point shortfall or whether the target is at risk. Any figure below 55% would signal material execution risk against the 2027 deadline.​

Recycling rate recovery and waste trajectory. The combined recycling rate fell from 40% in 2023 to 36.8% in 2024, moving away from the 50% target that effectively expired with 2025. The 2025 ESG Disclosure Supplement, expected mid-2025 in historical cadence, will reveal whether AbbVie restates, revises, or drops the recycling target. A continued decline would signal that the circular economy pillar of AbbVie’s ESG program lacks operational traction.​

Renewable electricity sourcing gap vs. 2030 trajectory. Active renewable electricity sourcing stands at 55.5% as of 2023, with 100% required by 2030. The company must add approximately 7.5 percentage points per year to stay on schedule. A 2024 figure below 60% would indicate the company is falling behind pace, putting the SBTi Scope 2 target and the 25–30% projected Scope 2 reduction at risk.

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/decarbonization-plan.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf

AbbVie has built a credible, data-supported ESG program anchored by SBTi-validated near-term targets, EY-assured KPIs, and a structured five-lever decarbonization plan. The 32.4% Scope 1+2 reduction from a 2021 baseline by 2024 is a genuine operational achievement, driven by aggressive renewable energy procurement and post-Allergan footprint consolidation. Patient access metrics are strong, with myAbbVie Assist serving 238,749 patients at no cost in 2024 and R&D investment reaching $10.8B, signaling that the healthcare access dimension of ESG is substantively funded.

The gaps are real. The recycling rate decline to 36.8% in 2024, the missed water target, and the 2024 waste uptick all point to a circular economy program that has not yet translated sustainability ambitions into reliable operational outcomes. The Scope 3 supplier gap (41.6% vs. 79.1% required) is the highest-risk item in the entire framework, given the compressed timeline and absence of a published 2024 update. Compared to Pfizer’s 65% supplier coverage, AbbVie is visibly behind on supply chain decarbonization.

Three strategic takeaways stand out for practitioners benchmarking or replicating AbbVie’s approach:

• Anchor decarbonization in capital allocation, not aspiration. AbbVie’s centralized CapEx fund for energy efficiency and GHG projects is a structural mechanism that explains why Scope 1+2 reductions have been consistent even through post-acquisition integration; this model is more replicable than voluntary project pipelines.
• Close the circular economy credibility gap before publishing new targets. A declining recycling rate toward the target deadline and a waste uptick in the most recent year are red flags for ESG credibility. Practitioners should treat packaging and waste-recycling KPIs as early-warning indicators of broader operational ESG integration, not as cosmetic commitments.
• Treat Scope 3 supplier engagement as a multi-year program requiring dedicated resourcing. AbbVie’s trajectory from 13.4% (2021) to 41.6% (2023) shows progress, but the pace must nearly double to reach 79.1% by 2027; companies that rely on passive supplier communication rather than active engagement programs with monitoring and escalation will fall short of SBTi supplier targets.

Source

https://www.abbvie.com/content/dam/abbvie-com2/pdfs/abbvie-esg-action-report.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf
https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/decarbonization-plan.pdf
https://thesustainableinnovation.com/pfizer-sustainability/